All In MedTech

FDA Clearance Tracker · P060040-S015

THORATEC HEARTMATE II LVAS

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 5, 2012 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 5, 2012

Approved

Time to decision

113 days

Received Feb 13, 2012. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P060040-S015
Device name
THORATEC HEARTMATE II LVAS
Applicant location
Pleasanton, CA
Received
Feb 13, 2012
Decided
Jun 5, 2012
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P060040

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code DSQ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR UPDATING THE HEARTMATE II LVAS INSTRUCTIONS FOR USE TO REFLECT THE POST-APPROVAL STUDY FINDINGS FOR THE BRIDGE-TO-TRANSPLANT INDICATION.

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.